News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,750 Results
Type
Article (43157)
Company Profile (307)
Press Release (686273)
Multimedia
Podcasts (101)
Webinars (17)
Section
Business (210724)
Career Advice (2100)
Deals (36687)
Drug Delivery (111)
Drug Development (83234)
Employer Resources (175)
FDA (16694)
Job Trends (15462)
News (356717)
Policy (34062)
Tag
Academia (2601)
Accelerated approval (14)
Adcomms (25)
Allergies (114)
Alliances (51581)
ALS (130)
Alzheimer's disease (1539)
Antibody-drug conjugate (ADC) (178)
Approvals (16746)
Artificial intelligence (374)
Autoimmune disease (41)
Automation (23)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (140)
Biotechnology (188)
Bladder cancer (111)
Brain cancer (43)
Breast cancer (416)
Cancer (3355)
Cardiovascular disease (283)
Career advice (1768)
Career pathing (33)
CAR-T (206)
CDC (40)
Cell therapy (555)
Cervical cancer (27)
Clinical research (69047)
Collaboration (1215)
Company closure (4)
Compensation (843)
Complete response letters (43)
COVID-19 (2732)
CRISPR (73)
C-suite (488)
Cystic fibrosis (124)
Data (3746)
Decentralized trials (2)
Denatured (32)
Depression (85)
Diabetes (396)
Diagnostics (6575)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (168)
Drug pricing (152)
Drug shortages (31)
Duchenne muscular dystrophy (172)
Earnings (90254)
Editorial (46)
Employer branding (21)
Employer resources (151)
Events (117551)
Executive appointments (911)
FDA (18868)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1060)
Gene editing (154)
Generative AI (27)
Gene therapy (447)
GLP-1 (886)
Government (4706)
Grass and pollen (6)
Guidances (332)
Healthcare (19036)
HIV (42)
Huntington's disease (33)
IgA nephropathy (49)
Immunology and inflammation (195)
Immuno-oncology (14)
Indications (46)
Infectious disease (2926)
Inflammatory bowel disease (166)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (165)
Interviews (326)
IPO (16882)
IRA (55)
Job creations (4066)
Job search strategy (1494)
Kidney cancer (13)
Labor market (64)
Layoffs (549)
Leadership (24)
Legal (8407)
Liver cancer (84)
Longevity (12)
Lung cancer (481)
Lymphoma (245)
Machine learning (22)
Management (59)
Manufacturing (530)
MASH (113)
Medical device (13644)
Medtech (13661)
Mergers & acquisitions (20610)
Metabolic disorders (983)
Multiple sclerosis (111)
NASH (17)
Neurodegenerative disease (160)
Neuropsychiatric disorders (40)
Neuroscience (2379)
NextGen: Class of 2025 (6642)
Non-profit (4541)
Now hiring (53)
Obesity (482)
Opinion (255)
Ovarian cancer (111)
Pain (154)
Pancreatic cancer (142)
Parkinson's disease (202)
Partnered (24)
Patents (372)
Patient recruitment (264)
Peanut (55)
People (60019)
Pharmaceutical (91)
Pharmacy benefit managers (23)
Phase I (21393)
Phase II (30385)
Phase III (22743)
Pipeline (2422)
Policy (246)
Postmarket research (2655)
Preclinical (9136)
Press Release (68)
Prostate cancer (164)
Psychedelics (41)
Radiopharmaceuticals (261)
Rare diseases (546)
Real estate (6278)
Recruiting (68)
Regulatory (24007)
Reports (51)
Research institute (2384)
Resumes & cover letters (359)
Rett syndrome (11)
RNA editing (12)
RSV (55)
Schizophrenia (116)
Series A (176)
Series B (132)
Service/supplier (12)
Sickle cell disease (71)
Special edition (22)
Spinal muscular atrophy (151)
Sponsored (35)
Startups (3746)
State (2)
Stomach cancer (15)
Supply chain (88)
Tariffs (81)
The Weekly (67)
Vaccines (889)
Venture capital (59)
Weight loss (313)
Women's health (51)
Worklife (17)
Date
Today (158)
Last 7 days (492)
Last 30 days (2309)
Last 365 days (31368)
2025 (22077)
2024 (35770)
2023 (40630)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35772)
2017 (33137)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28498)
Location
Africa (788)
Alabama (69)
Alaska (7)
Arizona (268)
Arkansas (14)
Asia (41374)
Australia (6609)
California (8601)
Canada (2666)
China (804)
Colorado (361)
Connecticut (368)
Delaware (229)
Europe (88547)
Florida (1284)
Georgia (287)
Hawaii (2)
Idaho (60)
Illinois (696)
India (42)
Indiana (414)
Iowa (17)
Japan (267)
Kansas (116)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1144)
Massachusetts (6343)
Michigan (268)
Minnesota (507)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2356)
New Mexico (29)
New York (2340)
North Carolina (1216)
North Dakota (8)
Northern California (3894)
Ohio (262)
Oklahoma (18)
Oregon (40)
Pennsylvania (1820)
Puerto Rico (17)
Rhode Island (41)
South America (1165)
South Carolina (44)
South Dakota (1)
Southern California (3303)
Tennessee (138)
Texas (1331)
United States (31448)
Utah (256)
Virginia (222)
Washington D.C. (75)
Washington State (720)
West Virginia (4)
Wisconsin (75)
729,750 Results for "lexicon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain, according to analysts at Jefferies.
September 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Lexicon Pharmaceuticals to Participate at Two Upcoming September 2025 Investor Conferences
August 28, 2025
·
1 min read
Press Releases
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
September 12, 2025
·
4 min read
Press Releases
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
September 4, 2025
·
4 min read
Press Releases
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 1, 2025
·
1 min read
Press Releases
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
September 5, 2025
·
4 min read
Press Releases
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
September 9, 2025
·
4 min read
Press Releases
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
·
10 min read
Press Releases
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
July 24, 2025
·
1 min read
Press Releases
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
·
1 min read
1 of 72,975
Next
